Tech Company Financing Transactions
Aro Biotherapeutics Funding Round
Aro Biotherapeutics closed a $13 million investment round on 12/12/2018. Investors included BioMotiv and Johnson & Johnson Development Corporation.
Transaction Overview
Company Name
Announced On
12/12/2018
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3675 Market St. 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Overview
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Susan Dillon
Chief Scientific Officer
Karyn O'Neil
VP - Administration
Mark Laurenzi
VP - Bus. Development
Scott Greenberg
VP - R & D
Steven Nadler
Browse more venture capital transactions:
Prev: 12/12/2018: GenEdit venture capital transaction
Next: 12/12/2018: Ingo Money venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs